Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, Harvie P, Bermudes D, Mayer L.

Leuk Res. 2009 Jan;33(1):129-39. doi: 10.1016/j.leukres.2008.06.028. Epub 2008 Aug 3.

PMID:
18676016
2.

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.

Lim WS, Tardi PG, Dos Santos N, Xie X, Fan M, Liboiron BD, Huang X, Harasym TO, Bermudes D, Mayer LD.

Leuk Res. 2010 Sep;34(9):1214-23. doi: 10.1016/j.leukres.2010.01.015. Epub 2010 Feb 6.

PMID:
20138667
3.

Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.

Lim WS, Tardi PG, Xie X, Fan M, Huang R, Ciofani T, Harasym TO, Mayer LD.

Leuk Lymphoma. 2010 Aug;51(8):1536-42. doi: 10.3109/10428194.2010.490312.

PMID:
20528246
4.

Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.

Kim HP, Gerhard B, Harasym TO, Mayer LD, Hogge DE.

Exp Hematol. 2011 Jul;39(7):741-50. doi: 10.1016/j.exphem.2011.04.001. Epub 2011 Apr 9.

PMID:
21530609
5.

Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse.

Bayne WF, Mayer LD, Swenson CE.

J Pharm Sci. 2009 Jul;98(7):2540-8. doi: 10.1002/jps.21620.

PMID:
19009594
6.

Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin.

Dicko A, Kwak S, Frazier AA, Mayer LD, Liboiron BD.

Int J Pharm. 2010 May 31;391(1-2):248-59. doi: 10.1016/j.ijpharm.2010.02.014. Epub 2010 Feb 13.

PMID:
20156541
7.

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.

Carol H, Fan MM, Harasym TO, Boehm I, Mayer LD, Houghton P, Smith MA, Lock RB.

Pediatr Blood Cancer. 2015 Jan;62(1):65-71. doi: 10.1002/pbc.25133. Epub 2014 Sep 9.

8.

Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells.

Gu C, Ye T, Wells RA.

Leuk Res. 2006 Nov;30(11):1447-51. Epub 2006 May 15.

PMID:
16704876
9.

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.

Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS.

Mol Cancer Ther. 2006 Jul;5(7):1854-63.

10.

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.

Feldman EJ, Kolitz JE, Trang JM, Liboiron BD, Swenson CE, Chiarella MT, Mayer LD, Louie AC, Lancet JE.

Leuk Res. 2012 Oct;36(10):1283-9. doi: 10.1016/j.leukres.2012.07.006. Epub 2012 Jul 26.

PMID:
22840315
11.

Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals.

Ying X, Wen H, Lu WL, Du J, Guo J, Tian W, Men Y, Zhang Y, Li RJ, Yang TY, Shang DW, Lou JN, Zhang LR, Zhang Q.

J Control Release. 2010 Jan 25;141(2):183-92. doi: 10.1016/j.jconrel.2009.09.020. Epub 2009 Sep 30.

PMID:
19799948
13.
14.

The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers.

Shao M, Sun SL, Li MH, Li BX, Yu H, Shen ZY, Ren YC, Hao ZF, Chang ND, Peng HS, Yang BF.

J Liposome Res. 2012 Jun;22(2):168-76. doi: 10.3109/08982104.2012.668552. Epub 2012 Mar 19.

PMID:
22428938
15.

Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.

Morris KL, Adams JA, Liu Yin JA.

Leuk Res. 2009 Aug;33(8):1096-9. doi: 10.1016/j.leukres.2009.01.025. Epub 2009 Mar 5.

PMID:
19268363
16.

Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors.

Forssen EA, Coulter DM, Proffitt RT.

Cancer Res. 1992 Jun 15;52(12):3255-61.

17.

Effects of fluidity and vesicle size on antitumor activity and myelosuppressive activity of liposomes loaded with daunorubicin.

Nagayasu A, Shimooka T, Kinouchi Y, Uchiyama K, Takeichi Y, Kiwada H.

Biol Pharm Bull. 1994 Jul;17(7):935-9.

PMID:
8000381
18.

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.

Tardi PG, Dos Santos N, Harasym TO, Johnstone SA, Zisman N, Tsang AW, Bermudes DG, Mayer LD.

Mol Cancer Ther. 2009 Aug;8(8):2266-75. doi: 10.1158/1535-7163.MCT-09-0243. Epub 2009 Aug 11.

19.

Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.

Zucker D, Barenholz Y.

J Control Release. 2010 Sep 15;146(3):326-33. doi: 10.1016/j.jconrel.2010.05.024. Epub 2010 May 25.

PMID:
20685223
20.

Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue.

Forssen EA, Malé-Brune R, Adler-Moore JP, Lee MJ, Schmidt PG, Krasieva TB, Shimizu S, Tromberg BJ.

Cancer Res. 1996 May 1;56(9):2066-75.

Supplemental Content

Support Center